Leap Therapeutics announced on Oct 9, 2025 that it has closed a private placement led by Winklevoss Capital, raising $58,888,888 in cash. The transaction involved the issuance of 15,212,311 shares of common stock, pre‑funded warrants covering up to 80,768,504 shares, and warrants to purchase an additional 71,985,605 shares at an exercise price of $0.5335 per share.
The capital infusion will support Leap’s digital asset treasury strategy and provide funds for continued development of its lead antibody programs, sirexatamab (DKN‑01) and FL‑501. The deal also expands the board to 12 members, with Winklevoss Capital entitled to nominate two directors, one of whom will serve as board chair.
The closing of the private placement marks a significant financing milestone for Leap, bolstering its liquidity position amid ongoing strategic realignment and a critical cash runway. The transaction underscores the company’s commitment to pursuing its therapeutic pipeline while exploring broader digital asset opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.